In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Calcium channel blocker monotherapy versus combination with renin-angiotensin system blockers in the development of new-onset diabetes mellitus in hypertensive Korean patients

Session Hypertension treatment

Speaker Ae-Young Her

Event : ESC Congress 2018

  • Topic : hypertension
  • Sub-topic : Hypertension: Treatment, Other
  • Session type : Moderated Posters

Authors : YH Kim (Chuncheon City,KR), A-Y Her (Chuncheon City,KR), S-W Rha (Seoul,KP), BG Choi (Seoul,KP), A Mashaly (Seoul,KP), Y Park (Seoul,KP), WY Jang (Seoul,KP), W Kim (Seoul,KP), JY Choi (Seoul,KP), EJ Park (Seoul,KP), JO Na (Seoul,KP), CU Choi (Seoul,KP), EJ Kim (Seoul,KP), CG Park (Seoul,KP), HS Seo (Seoul,KP)

Authors:
Y.H. Kim1 , A.-Y. Her1 , S.-W. Rha2 , B.G. Choi2 , A. Mashaly2 , Y. Park2 , W.Y. Jang2 , W. Kim2 , J.Y. Choi2 , E.J. Park2 , J.O. Na2 , C.U. Choi2 , E.J. Kim2 , C.G. Park2 , H.S. Seo2 , 1Kangwon National University Hospital - Chuncheon City - Korea Republic of , 2Korea University Guro Hospital - Seoul - Korea Republic of ,

Citation:
European Heart Journal ( 2018 ) 39 ( Supplement ), 663

Background: Among the antihypertensive drugs, the development of new-onset diabetes mellitus (NODM) is unchanged or increased by thiazide diuretics and beta-blockers and unchanged or decreased by angiotensin converting enzyme inhibitors (ACEI), calcium channel blockers (CCB), and angiotensin receptor blockers (ARB). The aim of this study was to investigate whether there are additional beneficial actions of combination therapy of renin-angiotensin system inhibitors (RASI) which include ACEI or ARB, with CCB over CCB monotherapy in the development of NODM during 5 years follow-up periods.

Methods: A total of 3208 consecutive hypertensive patients without a history of diabetes mellitus who prescribed CCB were retrospectively enrolled using the electronic database of Korea University Guro Hospital from January 2004 to December 2012. They were divided into the two groups according to the additional use of RASI (the RASI group, n=1,221 and the no RASI group, n=1,987). Primary endpoint was NODM, defined as a fasting blood glucose ≥126mg/dL or hemoglobin A1c ≥6.5%. Secondary endpoint were individual and composite major adverse cardiac events (MACE) defined as total death, cardiac death, myocardial infarction (MI) and percutaneous coronary intervention (PCI).

Results: After PSM analysis, two propensity-matched groups (939 pairs, n=1,878, C-statistic = 0.743) were generated and the baseline characteristics of the two groups were balanced. Up to 5 years, there were similar incidence of NODM (Hazard ratio [HR]; 0.975, 95% confidence interval [CI]; 0.697–1.362, p=0.880), MACE (HR; 1.000, 95% CI; 0.634–1.578, p=0.999), total death, MI, and PCI between the two groups (Figure).

Conclusions: In the present study, the use of RASI in addition to CCB did not show significant reduction of the development of NODM and individual and composite major clinical outcomes compared to CCB monotherapy up to 5 years.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are